Celldex Therapeutics (CLDX) Cash from Financing Activities (2010 - 2026)

Celldex Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $327000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 61.88% year-over-year to $327000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 54.63% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 99.46% from the prior year.
• Cash from Financing Activities slipped to $327000.0 in Q1 2026 per CLDX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $436.1 million in Q1 2024 and bottomed at $63000.0 in Q2 2025.
• The 5-year median for Cash from Financing Activities is $694000.0 (2023), against an average of $39.2 million.
• Across the five-year window, Cash from Financing Activities jumped 62740.35% in 2024 and sank 99.95% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $1.4 million in 2022, then surged by 15482.37% to $217.4 million in 2023, then sank by 99.82% to $386000.0 in 2024, then soared by 249.48% to $1.3 million in 2025, then sank by 75.76% to $327000.0 in 2026.
• Per Business Quant, the three latest CLDX Cash from Financing Activities figures stand at $327000.0 (Q1 2026), $1.3 million (Q4 2025), and $774000.0 (Q3 2025).